Ost-müük CytomX Therapeutics Inc - CTMX CFD
Lisa lemmikuks- Kokkuvõte
- Ajaloolised andmed
- Sündmused
- Tuluaruanne
- Bilanss
- Rahavood
- Omand
Hinnavahe | 0.05 | ||||||||
Pika positsiooni ööpäeva tasu
Long position overnight fee
Mine platvormile | -0.030779% | ||||||||
Lühikese positsiooni ööpäeva tasu
Short position overnight fee
Mine platvormile | -0.013666% | ||||||||
Ööpäeva tasu aeg | 22:00 (UTC) | ||||||||
Min kauplemise kogus | 1 | ||||||||
Valuuta | USD | ||||||||
Tagatis | 20% | ||||||||
Aktsiabörs | United States of America | ||||||||
Kauplemise vahendustasu | 0% |
*Information provided by Capital.com
Eelmine sulgemine* | 1.85 |
Avatud* | 1.78 |
Aastane muutus* | -3.78% |
Päeva ulatus* | 1.78 - 1.95 |
52 nädala ulatus | 1.17-4.73 |
Keskmine maht (10 päeva) | 1.59M |
Keskmine maht (3 kuud) | 67.17M |
Turukapitalisatsioon | 181.73M |
P/E suhtarv | -100.00K |
Ringluses olevad aktsiad | 66.08M |
Tulu | 71.94M |
EPS | -1.49 |
Dividendid (% kasumist) | N/A |
Beeta | 0.66 |
Järgmine tuluaruande kuupäev | Feb 27, 2023 |
Kõigi andmete allikas on Refinitiv, välja arvatud tärniga märgitud, kus *-ga andmed on esitanud Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Sulgemishind | Change (%) | Avamishind | High | Low |
---|---|---|---|---|---|---|
Jun 29, 2022 | 1.86 | 0.04 | 2.20% | 1.82 | 1.96 | 1.78 |
Jun 28, 2022 | 1.85 | -0.09 | -4.64% | 1.94 | 1.94 | 1.80 |
Jun 27, 2022 | 1.92 | 0.04 | 2.13% | 1.88 | 1.97 | 1.83 |
Jun 24, 2022 | 1.87 | -0.05 | -2.60% | 1.92 | 1.97 | 1.83 |
Jun 23, 2022 | 1.84 | 0.14 | 8.24% | 1.70 | 1.85 | 1.70 |
Jun 22, 2022 | 1.77 | 0.12 | 7.27% | 1.65 | 1.81 | 1.62 |
Jun 21, 2022 | 1.68 | 0.06 | 3.70% | 1.62 | 1.71 | 1.58 |
Jun 17, 2022 | 1.58 | -0.03 | -1.86% | 1.61 | 1.70 | 1.57 |
Jun 16, 2022 | 1.63 | -0.04 | -2.40% | 1.67 | 1.67 | 1.57 |
Jun 15, 2022 | 1.70 | 0.07 | 4.29% | 1.63 | 1.73 | 1.61 |
Jun 14, 2022 | 1.65 | -0.05 | -2.94% | 1.70 | 1.72 | 1.64 |
Jun 13, 2022 | 1.71 | -0.03 | -1.72% | 1.74 | 1.76 | 1.68 |
Jun 10, 2022 | 1.83 | -0.02 | -1.08% | 1.85 | 1.85 | 1.77 |
Jun 9, 2022 | 1.92 | 0.07 | 3.78% | 1.85 | 1.93 | 1.81 |
Jun 8, 2022 | 1.88 | 0.02 | 1.08% | 1.86 | 1.98 | 1.86 |
Jun 7, 2022 | 1.86 | 0.16 | 9.41% | 1.70 | 1.91 | 1.67 |
Jun 6, 2022 | 1.71 | -0.06 | -3.39% | 1.77 | 1.83 | 1.71 |
Jun 3, 2022 | 1.76 | 0.22 | 14.29% | 1.54 | 1.78 | 1.54 |
Jun 2, 2022 | 1.58 | 0.06 | 3.95% | 1.52 | 1.59 | 1.49 |
Jun 1, 2022 | 1.53 | -0.05 | -3.16% | 1.58 | 1.67 | 1.50 |
CytomX Therapeutics Inc Events
Time (UTC) | Country | Event |
---|---|---|
No events scheduled |
- Aastas
- Kvartalis
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
---|---|---|---|---|---|---|
Kogutulu | 15.043 | 71.623 | 59.502 | 57.489 | 100.362 | 69.573 |
Tulu | 15.043 | 71.623 | 59.502 | 57.489 | 100.362 | 69.573 |
Kogu tegevuskulu | 74.629 | 117.882 | 137.376 | 168.384 | 148.967 | 153.354 |
Müük/Üldine/admin kulud, kokku | 19.874 | 25.605 | 33.51 | 36.765 | 36.031 | 39.16 |
Uuringud ja arendus | 54.755 | 92.277 | 103.866 | 131.619 | 112.936 | 114.194 |
Tulud majandustegevusest | -59.586 | -46.259 | -77.874 | -110.895 | -48.605 | -83.781 |
Intressitulud (kulu), muud tulud, neto | 0.736 | 2.674 | 7.641 | 8.365 | 1.836 | 0.255 |
Muud, neto | -0.069 | -0.027 | -0.068 | -0.135 | -0.027 | -0.083 |
Netotulu enne makse | -58.919 | -43.612 | -70.301 | -102.665 | -46.796 | -83.609 |
Netotulu pärast makse | -58.9 | -68.799 | -84.604 | -102.238 | -32.885 | -83.609 |
Netotulu enne erikulusid | -58.9 | -68.799 | -84.604 | -102.238 | -32.885 | -83.609 |
Netotulu | -58.9 | -43.099 | -84.604 | -102.238 | -32.885 | -83.609 |
Total Adjustments to Net Income | 0 | 0 | ||||
Arvestatav tulu, v a erikulud | -58.9 | -68.799 | -84.604 | -102.238 | -32.885 | -83.609 |
Arvestatav tulu, koos erikuludega | -58.9 | -43.099 | -84.604 | -102.238 | -32.885 | -83.609 |
Jaotamisele kuuluv netotulu | -58.9 | -43.099 | -84.604 | -102.238 | -32.885 | -83.609 |
Keskmine jaotamisele kuuluv aktsia kohta | 36.2347 | 37.1668 | 41.6644 | 45.3359 | 46.1456 | 64.1469 |
Jaotatav EPS, v a erakorralised kulud | -1.62551 | -1.85109 | -2.03061 | -2.25512 | -0.71264 | -1.3034 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | |||
Jaotamisele kuuluv normaal-EPS | -1.62551 | -1.85109 | -2.03061 | -2.25512 | -0.71264 | -1.3034 |
Erakorralised kulud kokku | 25.7 |
Q1 2021 | Q2 2021 | Q3 2021 | Q4 2021 | Q1 2022 | |
---|---|---|---|---|---|
Kogutulu | 15.971 | 16.288 | 17.587 | 19.727 | 17.136 |
Tulu | 15.971 | 16.288 | 17.587 | 19.727 | 17.136 |
Kogu tegevuskulu | 31.598 | 35.493 | 40.228 | 46.035 | 41.102 |
Müük/Üldine/admin kulud, kokku | 9.227 | 9.393 | 11.085 | 9.456 | 10.543 |
Uuringud ja arendus | 22.371 | 26.1 | 29.143 | 36.579 | 30.559 |
Tulud majandustegevusest | -15.627 | -19.205 | -22.641 | -26.308 | -23.966 |
Intressitulud (kulu), muud tulud, neto | 0.068 | 0.044 | 0.07 | 0.073 | 0.068 |
Muud, neto | 0.005 | -0.082 | -0.013 | 0.007 | 0.013 |
Netotulu enne makse | -15.554 | -19.243 | -22.584 | -26.228 | -23.885 |
Netotulu pärast makse | -15.554 | -19.243 | -22.584 | -26.228 | -23.885 |
Netotulu enne erikulusid | -15.554 | -19.243 | -22.584 | -26.228 | -23.885 |
Netotulu | -15.554 | -19.243 | -22.584 | -26.228 | -23.885 |
Arvestatav tulu, v a erikulud | -15.554 | -19.243 | -22.584 | -26.228 | -23.885 |
Arvestatav tulu, koos erikuludega | -15.554 | -19.243 | -22.584 | -26.228 | -23.885 |
Jaotamisele kuuluv netotulu | -15.554 | -19.243 | -22.584 | -26.228 | -23.885 |
Keskmine jaotamisele kuuluv aktsia kohta | 60.9681 | 65.056 | 65.2081 | 65.3086 | 65.3937 |
Jaotatav EPS, v a erakorralised kulud | -0.25512 | -0.29579 | -0.34634 | -0.4016 | -0.36525 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
Jaotamisele kuuluv normaal-EPS | -0.25512 | -0.29579 | -0.34634 | -0.4016 | -0.36525 |
- Aastas
- Kvartalis
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
---|---|---|---|---|---|---|
Käibevarad kokku | 188.147 | 388.601 | 445.475 | 303.335 | 324.013 | 310.301 |
Raha ja lühiajalised investeeringud | 181.938 | 374.11 | 436.127 | 296.145 | 316.119 | 305.226 |
Raha ja ekvivalendid | 104.645 | 177.548 | 247.577 | 188.425 | 191.859 | 205.53 |
Lühiajalised investeeringud | 77.293 | 196.562 | 188.55 | 107.72 | 124.26 | 99.696 |
Laekumata arved, neto | 2.313 | 10.139 | 0.097 | 0.013 | 0.798 | 0.79 |
Accounts Receivable - Trade, Net | 2.313 | 10.139 | 0.097 | 0.013 | 0.798 | 0.79 |
Prepaid Expenses | 3.896 | 4.352 | 9.251 | 7.177 | 7.096 | 4.285 |
Total Assets | 199.128 | 397.644 | 457.108 | 341.282 | 358.663 | 339.411 |
Property/Plant/Equipment, Total - Net | 4.392 | 4.218 | 6.934 | 32.754 | 29.445 | 25.322 |
Property/Plant/Equipment, Total - Gross | 8.135 | 9.426 | 13.88 | 41.804 | 40.871 | 39.154 |
Accumulated Depreciation, Total | -3.743 | -5.208 | -6.946 | -9.05 | -11.426 | -13.832 |
Goodwill, Net | 0.949 | 0.949 | 0.949 | 0.949 | 0.949 | 0.949 |
Intangibles, Net | 1.75 | 1.604 | 1.458 | 1.312 | 1.167 | 1.021 |
Other Long Term Assets, Total | 3.89 | 2.272 | 2.292 | 2.932 | 3.089 | 1.818 |
Total Current Liabilities | 35.767 | 61.147 | 97.908 | 85.59 | 100.924 | 106.316 |
Accounts Payable | 6.596 | 4.205 | 5.132 | 4.158 | 2.996 | 2.818 |
Accrued Expenses | 8.824 | 16.383 | 26.724 | 30.051 | 23.059 | 34.236 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities, Total | 20.347 | 40.559 | 66.052 | 51.381 | 74.869 | 69.262 |
Total Liabilities | 120.649 | 327.748 | 326.225 | 290.169 | 308.86 | 250.032 |
Total Long Term Debt | 0 | 0 | 0 | 0 | 0 | 0 |
Deferred Income Tax | 0.513 | |||||
Other Liabilities, Total | 84.369 | 266.601 | 228.317 | 204.579 | 207.936 | 143.716 |
Total Equity | 78.479 | 69.896 | 130.883 | 51.113 | 49.803 | 89.379 |
Common Stock | 0.001 | 0.001 | 0.001 | 0.001 | 0.001 | 0.001 |
Additional Paid-In Capital | 254.871 | 289.454 | 445.956 | 468.285 | 499.964 | 623.344 |
Retained Earnings (Accumulated Deficit) | -176.366 | -219.465 | -314.981 | -417.23 | -450.115 | -533.724 |
Other Equity, Total | -0.027 | -0.094 | -0.093 | 0.057 | -0.047 | -0.242 |
Total Liabilities & Shareholders’ Equity | 199.128 | 397.644 | 457.108 | 341.282 | 358.663 | 339.411 |
Total Common Shares Outstanding | 36.4902 | 38.4786 | 45.0832 | 45.5231 | 48.2518 | 65.3928 |
Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 |
Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
---|---|---|---|---|---|
Käibevarad kokku | 400.008 | 271.005 | 240.998 | 310.301 | 268.444 |
Raha ja lühiajalised investeeringud | 393.796 | 266.177 | 236.289 | 305.226 | 262.53 |
Raha ja ekvivalendid | 329.666 | 256.146 | 236.284 | 205.53 | 163.488 |
Lühiajalised investeeringud | 64.13 | 10.031 | 0.005 | 99.696 | 99.042 |
Laekumata arved, neto | 0.756 | 0.931 | 0.887 | 0.79 | 1.016 |
Accounts Receivable - Trade, Net | 0.756 | 0.931 | 0.887 | 0.79 | 1.016 |
Prepaid Expenses | 5.456 | 3.897 | 3.822 | 4.285 | 4.898 |
Total Assets | 434.158 | 402.44 | 371.233 | 339.411 | 296.825 |
Property/Plant/Equipment, Total - Net | 28.908 | 27.66 | 26.441 | 25.322 | 24.629 |
Goodwill, Net | 0.949 | 0.949 | 0.949 | 0.949 | 0.949 |
Intangibles, Net | 1.13 | 1.094 | 1.057 | 1.021 | 0.984 |
Other Long Term Assets, Total | 3.163 | 1.818 | 1.819 | 1.818 | 1.819 |
Total Current Liabilities | 98.049 | 93.377 | 99.772 | 106.316 | 102.766 |
Accounts Payable | 2.582 | 1.755 | 1.516 | 2.818 | 1.721 |
Accrued Expenses | 18.831 | 19.253 | 25.167 | 34.236 | 31.032 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities, Total | 76.636 | 72.369 | 73.089 | 69.262 | 70.013 |
Total Liabilities | 288.136 | 271.487 | 259.559 | 250.032 | 228.631 |
Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Liabilities, Total | 190.087 | 178.11 | 159.787 | 143.716 | 125.865 |
Total Equity | 146.022 | 130.953 | 111.674 | 89.379 | 68.194 |
Preferred Stock - Non Redeemable, Net | 0 | 0 | |||
Common Stock | 0.001 | 0.001 | 0.001 | 0.001 | 0.001 |
Additional Paid-In Capital | 611.733 | 615.849 | 619.117 | 623.344 | 626.721 |
Retained Earnings (Accumulated Deficit) | -465.669 | -484.912 | -507.496 | -533.724 | -557.609 |
Other Equity, Total | -0.043 | 0.015 | 0.052 | -0.242 | -0.919 |
Total Liabilities & Shareholders’ Equity | 434.158 | 402.44 | 371.233 | 339.411 | 296.825 |
Total Common Shares Outstanding | 65.0029 | 65.157 | 65.2491 | 65.3928 | 65.3984 |
Long Term Investments | 99.914 | 99.969 |
- Aastas
- Kvartalis
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
---|---|---|---|---|---|---|
Netotulu/algväärtus | -58.9 | -43.099 | -84.604 | -102.238 | -32.885 | -83.609 |
Raha majandustegevusest | -2.032 | 170.373 | -75.521 | -140.48 | 5.259 | -119.031 |
Raha majandustegevusest | 1.733 | 1.645 | 1.884 | 2.459 | 2.427 | 2.56 |
Deferred Taxes | 0.006 | -0.513 | ||||
Mittelikviidsed varad | 11.869 | 22.375 | 15.177 | 18.474 | 17.437 | 16.572 |
Muutused tööjõus | 43.26 | 189.965 | -7.978 | -59.321 | 18.134 | -54.7 |
Tulu investeeringutelt | 45.859 | -121.266 | 5.926 | 79.701 | -18.718 | 22.489 |
Kapitalikulutused | -2.176 | -1.559 | -3.788 | -3.497 | -2.309 | -1.609 |
Muud rahavood investeeringutelt, kokku | 48.035 | -119.707 | 9.714 | 83.198 | -16.409 | 24.098 |
Rahavood investeeringutelt | 0.996 | 23.796 | 139.624 | 1.627 | 16.893 | 110.213 |
Rahavoogudesse investeerimine | -0.012 | 0 | 0 | |||
Aktsiate emiteerimine (tagasiost), neto | 0.93 | 23.796 | 139.624 | 1.627 | 16.893 | 110.213 |
Laenu väljastamine (kustutamine), neto | 0.078 | 0 | ||||
Rahaline kogumuutus | 44.823 | 72.903 | 70.029 | -59.152 | 3.434 | 13.671 |
Amortization | 0.146 | 0.146 | 0.146 | |||
Cash Taxes Paid | 13.061 | 0 | 0 |
Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | -15.554 | -34.797 | -57.381 | -83.609 | -23.885 |
Cash From Operating Activities | -29.94 | -58.139 | -87.839 | -119.031 | -41.313 |
Cash From Operating Activities | 0.638 | 1.278 | 1.921 | 2.56 | 0.565 |
Amortization | 0.036 | 0.073 | 0.11 | 0.146 | 0.037 |
Non-Cash Items | 3.934 | 8.274 | 12.235 | 16.572 | 4.179 |
Changes in Working Capital | -18.994 | -32.967 | -44.724 | -54.7 | -22.209 |
Cash From Investing Activities | 59.012 | 13 | 22.734 | 22.489 | -0.736 |
Capital Expenditures | -0.982 | -1.096 | -1.364 | -1.609 | -0.736 |
Other Investing Cash Flow Items, Total | 59.994 | 14.096 | 24.098 | 24.098 | 0 |
Cash From Financing Activities | 108.735 | 109.426 | 109.53 | 110.213 | 0.007 |
Issuance (Retirement) of Stock, Net | 108.735 | 109.426 | 109.53 | 110.213 | 0.007 |
Net Change in Cash | 137.807 | 64.287 | 44.425 | 13.671 | -42.042 |
Investori nimi | Investori liik | Ringluse protsent | Hoitud osakud | Muutus osakutes | Hoidmise kuupäev | Hinnang käibele |
---|---|---|---|---|---|---|
BVF Partners L.P. | Hedge Fund | 9.9809 | 6595801 | 0 | 2022-09-30 | LOW |
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 6.8669 | 4537961 | -540426 | 2022-09-30 | LOW |
Tang Capital Management, LLC | Hedge Fund | 5.2963 | 3500000 | 29100 | 2022-09-30 | MED |
Acadian Asset Management LLC | Investment Advisor/Hedge Fund | 4.0154 | 2653576 | 814350 | 2022-09-30 | MED |
Rubric Capital Management LP | Hedge Fund | 3.6415 | 2406449 | 0 | 2022-09-30 | MED |
Renaissance Technologies LLC | Hedge Fund | 2.7323 | 1805600 | 351339 | 2022-09-30 | HIGH |
BlackRock Institutional Trust Company, N.A. | Investment Advisor | 2.6528 | 1753118 | -24021 | 2022-09-30 | LOW |
Medical Strategy GmbH | Investment Advisor | 2.5583 | 1690646 | 0 | 2022-09-30 | LOW |
Laurion Capital Management LP | Hedge Fund | 1.9231 | 1270900 | 0 | 2022-09-30 | HIGH |
Platinum Asset Management | Investment Advisor/Hedge Fund | 1.8606 | 1229545 | 0 | 2022-09-30 | LOW |
Jacobs Levy Equity Management, Inc. | Investment Advisor/Hedge Fund | 1.7085 | 1129058 | 191388 | 2022-09-30 | MED |
Assenagon Asset Management S.A. | Investment Advisor | 1.3844 | 914900 | -150492 | 2022-12-31 | HIGH |
Two Sigma Investments, LP | Hedge Fund | 1.3397 | 885361 | 200477 | 2022-09-30 | HIGH |
Newtyn Management, LLC | Hedge Fund | 1.2106 | 800000 | -273400 | 2022-09-30 | MED |
Fidelity Management & Research Company LLC | Investment Advisor | 1.0354 | 684209 | -1637 | 2022-09-30 | LOW |
Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 0.8889 | 587451 | 4386 | 2022-09-30 | LOW |
Oasis Management Company Ltd. | Investment Advisor | 0.818 | 540541 | 0 | 2022-09-30 | MED |
Millennium Management LLC | Hedge Fund | 0.8058 | 532513 | -909219 | 2022-09-30 | HIGH |
Gluck (Frederick W) | Individual Investor | 0.8021 | 530069 | 0 | 2022-04-18 | LOW |
D. E. Shaw & Co., L.P. | Hedge Fund | 0.7409 | 489630 | 242153 | 2022-09-30 | HIGH |
Miks valida Capital.com? Meie numbrid räägivad iseenda eest.
Capital.com GroupKauplejad
Igakuiste aktiivsete klientide arv
Igakuine investeerimise maht
Igakuiselt välja võetud
Kauplemiskalkulaator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
CytomX Therapeutics Inc Company profile
Ettevõttest CytomX Therapeutics Inc
CytomX Therapeutics, Inc. on kliinilises staadiumis, onkoloogiale keskendunud biofarmatseutiline ettevõte. Ettevõte arendab oma Probody tehnoloogiaplatvormil põhinevaid uuritavaid tingimuslikult aktiveeritud ravimeid vähktõve raviks. Probody tehnoloogiaplatvormi eesmärk on võimaldada antikehapõhiste ravimite tingimuslikku aktiveerimist kasvaja mikrokeskkonnas, vähendades samal ajal ravimi aktiivsust tervetes kudedes ja ringluses. Ettevõtte tootekandidaatide hulka kuuluvad tingimuslikult aktiveeritud antikeha-ravimikonjugaadid (ADC) praluzatamab ravtansine (CX2009, suunatud CD166 vastu) ja CX-2029, suunatud CD71 vastu, ning Probody immuunsüsteemi kontrollpunkti inhibiitorid pacmilimab (CX-072, suunatud PD-L1 vastu) ja BMS-986249 (suunatud CTLA-4 vastu). Samuti on kaks prekliinilist ainet uue ravimi (IND) uuringutes - tingimuslikult aktiveeritud ADC, mis on suunatud EpCAM/Trop-1-le (CX-2043), ja tingimuslikult aktiveeritud T-rakkudega seotud bispetsiifiline antikeha, mis on suunatud EGFR-le ja CD3-le (CX-904).
Industry: | Bio Therapeutic Drugs |
650 Gateway Blvd.
Suite 125
SOUTH SAN FRANCISCO
CALIFORNIA 94080
US
Tuluaruanne
- Annual
- Quarterly
Teised on vaadanud veel
Kas otsite jätkuvalt vahendajat, keda saab usaldada?
Ühinege 500,000+ kauplejaga üle kogu maailma, kes valisid kauplemiseks veebisaidi Capital.com